Background: The recent emergence of the coronavirus disease 2019 (COVID-19) had been associated with increased reporting of invasive mucormycosis, with high morbidity and mortality rates. According to Roden et al., pulmonary mucormycosis is the second most common presentation. Various risk factors associated with pulmonary mucormycosis besides COVID-19. The purpose of this study is to analyze patients' demographic details, associated risk factors, and clinical and radiological findings and it confirms with histopathological examination for early diagnosis and management to improve outcomes. Materials and methods: This retrospective observational study was conducted on 16 patients with pulmonary mucormycosis confirmed with histopathology with a previous history of COVID-19 infection presenting to Pandit Dindayal Upadhyay Medical College Hospital, Rajkot, Gujarat, India, during the months of April–August 2021. We evaluated the patients' demographic details, clinical presentation, radiological findings, treatment, and outcomes. Results: We reported 16 cases with pulmonary mucormycosis; diagnosed after a mean of 36 days from the diagnosis of COVID-19. There was male predominance with a mean age of 54.5 years. Out of 16 patients, 14 (87.5%) survived, and 2 (12.5%) died during the course of treatment. The overall mortality rate was 12.5% in our study. Conclusion: The clinician should be aware of the possibility of pulmonary mucormycosis during and after the COVID-19 infection, especially in patients with underlying risk factors, and should enable early diagnosis and treatment to reduce morbidity and mortality to improve outcomes.